---
title: "Weekly Recap | Corcept Therap +0.11%, a choppy week ends higher"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300847094.md"
description: "Corcept Therap added 0.11% this week to close at $116.23, outperforming the S&P 500 by roughly 0.38 percentage points. The stock whipsawed: Monday hovered in a tight range, Tuesday pushed up to $120.51, the next two sessions pulled back to a weekly low of $111.94, and Friday reclaimed the $116 level. With no major catalyst, shares consolidated between roughly $112 and $120."
datetime: "2026-10-03T06:34:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300847094.md)
  - [en](https://longbridge.com/en/news/300847094.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300847094.md)
generator: "portal-rs"
---

# Weekly Recap | Corcept Therap +0.11%, a choppy week ends higher

## The Week

Corcept Therap added 0.11% this week to close at $116.23, outperforming the S&P 500 by roughly 0.38 percentage points. The stock whipsawed: Monday hovered in a tight range, Tuesday pushed up to $120.51, the next two sessions pulled back to a weekly low of $111.94, and Friday reclaimed the $116 level. With no major catalyst, shares consolidated between roughly $112 and $120.

## Analyst Ratings

Of the 5 firms covering the stock, 3 rate it buy, 1 rate it outperform and 1 rate it sell; none assign hold or underperform. The consensus rating is buy, with a consensus target of $141, about 21.3% above spot. Targets range widely from $50 to $165. The stock ranks 96th out of 203 names in the pharma sector for analyst ratings.

## The Week Ahead

The macro calendar is fairly busy: S&P Global services PMI final and ISM non-manufacturing PMI land Monday, trade balance data arrives Tuesday, and EIA crude inventories follow on Wednesday. There are no company-specific earnings events to track, so the main watch point is how macro data shapes risk appetite.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [CORT.US](https://longbridge.com/en/quote/CORT.US.md)

## Related News & Research

- [Corcept Therapeutics Director James N. Wilson Reports Sale of $1.15 Million in Common Shares](https://longbridge.com/en/news/302151299.md)
- [Corcept Therapeutics (CORT) Earnings And Pipeline Buzz Put Fair Value Back In Focus](https://longbridge.com/en/news/301194140.md)
- [AI fever ignites a boom in thematic ETFs as fund managers hunt for their next big hit](https://longbridge.com/en/news/302963080.md)
- [Cognex (CGNX) Reset Growth Expectations, Is The Stock Fully Priced?](https://longbridge.com/en/news/302944110.md)
- [Is Bunge Global (BG) A Bargain Before Its October 29 Earnings Report?](https://longbridge.com/en/news/302944813.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**